EA201792571A1 - Терапевтическое применение l-4-хлорокинуренина - Google Patents

Терапевтическое применение l-4-хлорокинуренина

Info

Publication number
EA201792571A1
EA201792571A1 EA201792571A EA201792571A EA201792571A1 EA 201792571 A1 EA201792571 A1 EA 201792571A1 EA 201792571 A EA201792571 A EA 201792571A EA 201792571 A EA201792571 A EA 201792571A EA 201792571 A1 EA201792571 A1 EA 201792571A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chlorokinurenin
therapeutic application
chloroquinurenin
diseases
treatment
Prior art date
Application number
EA201792571A
Other languages
English (en)
Inventor
Х. Ральф Снодграсс
Аллен Е. Като III
Джэк С. Хиклин
Original Assignee
Вистаджен Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вистаджен Терапьютикс, Инк. filed Critical Вистаджен Терапьютикс, Инк.
Publication of EA201792571A1 publication Critical patent/EA201792571A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Предоставлены фармацевтические композиции, включающие L-4-хлорокинуренин, и ассоциированные терапевтические способы для лечения определенных неврологических и прочих заболеваний.
EA201792571A 2015-05-22 2016-05-23 Терапевтическое применение l-4-хлорокинуренина EA201792571A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562179924P 2015-05-22 2015-05-22
PCT/US2016/033733 WO2016191351A1 (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine

Publications (1)

Publication Number Publication Date
EA201792571A1 true EA201792571A1 (ru) 2018-06-29

Family

ID=57393671

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792571A EA201792571A1 (ru) 2015-05-22 2016-05-23 Терапевтическое применение l-4-хлорокинуренина

Country Status (20)

Country Link
US (3) US20180140568A1 (ru)
EP (2) EP4108239A1 (ru)
JP (3) JP2018521007A (ru)
KR (1) KR20180015158A (ru)
CN (1) CN107949379A (ru)
AU (3) AU2016268153B2 (ru)
BR (1) BR112017024908A2 (ru)
CA (1) CA3024783A1 (ru)
DK (1) DK3297619T3 (ru)
EA (1) EA201792571A1 (ru)
ES (1) ES2925274T3 (ru)
HK (1) HK1257800A1 (ru)
IL (3) IL296380A (ru)
MX (1) MX2017014456A (ru)
PL (1) PL3297619T3 (ru)
PT (1) PT3297619T (ru)
SG (1) SG10202007661XA (ru)
SI (1) SI3297619T1 (ru)
WO (1) WO2016191351A1 (ru)
ZA (1) ZA201707874B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112933073A (zh) 2013-01-22 2021-06-11 维斯塔津治疗公司 L-4-氯犬尿氨酸的剂型和治疗用途
EP3952856A4 (en) * 2019-04-09 2023-01-11 Vistagen Therapeutics, Inc. GENE VARIANTS ASSOCIATED WITH RESPONSE TO THE TREATMENT OF NEUROLOGICAL DISORDERS
AU2021297249A1 (en) * 2020-06-24 2023-02-23 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
WO2022221423A1 (en) * 2021-04-13 2022-10-20 Vistagen Therapeutics, Inc. Treatment of autoimmune anti-nmda-receptor encephalitis
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
WO2024011105A1 (en) * 2022-07-05 2024-01-11 Mahana Therapeutics, Inc. Methods and systems for treating tinnitus using digital therapeutics

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
JP2009533393A (ja) * 2006-04-12 2009-09-17 プロビオドルグ エージー 酵素阻害薬
US8058243B2 (en) * 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
EP2212694A4 (en) * 2007-11-06 2011-10-12 Univ Emory METHOD OF IDENTIFYING SAFE NMDA RECEPTOR ANTAGONISTS
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
AU2013305580A1 (en) * 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
CN112933073A (zh) * 2013-01-22 2021-06-11 维斯塔津治疗公司 L-4-氯犬尿氨酸的剂型和治疗用途
JP2016513718A (ja) 2013-03-14 2016-05-16 ヴィスタゲン セラピューティクス、インコーポレイテッド キラルキヌレニン化合物及び中間体の合成
US9834801B2 (en) 2013-03-14 2017-12-05 Vistagen Therapeutics, Inc. Methods for the synthesis of chiral kynurenine compounds

Also Published As

Publication number Publication date
MX2017014456A (es) 2018-03-16
CA3024783A1 (en) 2016-12-01
US20180140568A1 (en) 2018-05-24
AU2016268153B2 (en) 2021-08-12
HK1257800A1 (zh) 2019-11-01
SI3297619T1 (sl) 2023-02-28
KR20180015158A (ko) 2018-02-12
IL296380A (en) 2022-11-01
EP3297619B1 (en) 2022-07-06
EP3297619A4 (en) 2019-01-02
AU2023282234A1 (en) 2024-01-18
WO2016191351A1 (en) 2016-12-01
ES2925274T3 (es) 2022-10-14
EP4108239A1 (en) 2022-12-28
JP2022064908A (ja) 2022-04-26
BR112017024908A2 (pt) 2018-07-31
DK3297619T3 (da) 2022-08-15
AU2021209279A1 (en) 2021-08-19
US20240122887A1 (en) 2024-04-18
US20190321317A1 (en) 2019-10-24
IL285882A (en) 2021-09-30
EP3297619A1 (en) 2018-03-28
AU2016268153A1 (en) 2017-12-14
PT3297619T (pt) 2022-08-05
IL255770B (en) 2021-09-30
AU2021209279B2 (en) 2023-09-14
PL3297619T3 (pl) 2023-02-13
JP2024050575A (ja) 2024-04-10
ZA201707874B (en) 2020-01-29
SG10202007661XA (en) 2020-09-29
CN107949379A (zh) 2018-04-20
JP2018521007A (ja) 2018-08-02
IL255770A (en) 2018-01-31

Similar Documents

Publication Publication Date Title
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201890204A1 (ru) Антибактериальные соединения
TW201613901A (en) New compounds
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201691582A1 (ru) Новые фармацевтические препараты
GB2541571A (en) Pharmaceutical compositions
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201990400A1 (ru) Соединения и композиции и их применение
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
ZA201703467B (en) Methods of treating ocular conditions
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use